Targeted treatment of advanced ovarian cancer: spotlight on rucaparib

References

• NooneAMHowladerNKrapchoMSEER Cancer statistics review, 1975–2015SEER Cancer Statistics Review Available from: https://seer.cancer.gov/statfacts/html/ovary.htmlAccessed May 21, 2018
   Google Scholar
• BristowREMontzFJLagasseLDLeuchterRSKarlanBYSurvival impact of surgical cytoreduction in stage IV epithelial ovarian cancerGynecol Oncol199972327828710053096
   PubMed Web of Science ®Google Scholar
• BristowBRETomacruzRSArmstrongDKMaximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era200820512481259
   Google Scholar
• ArmstrongDPlaxeSCAlvarezRDOvarian cancer2NCCN Clin Pract Guidel Oncol20182 Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#ovarianAccessed October 15, 2018
   Google Scholar
• VergoteIdu BoisAAmantFHeitzFLeunenKHarterPNeoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?Gynecol Oncol2013128161123006973
   PubMed Web of Science ®Google Scholar
• VergoteIAmantFKristensenGEhlenTReedNSCasadoAPrimary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancerEur J Cancer201147Suppl 3S88S9221944035
   PubMed Web of Science ®Google Scholar
• BristowREChiDSPlatinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysisGynecol Oncol200610331070107616875720
   PubMed Web of Science ®Google Scholar
• WagnerUMarthCLargillierRFinal overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patientsBr J Cancer2012107458859122836511
   PubMed Web of Science ®Google Scholar
• AghajanianCGoffBNycumLRWangYVHusainABlankSVFinal overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancerGynecol Oncol20151391101626271155
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEHilpertFWeberBBevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialJ Clin Oncol201432131302130824637997
   PubMed Web of Science ®Google Scholar
• SwisherEMLinKKOzaAMRucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trialLancet Oncol2017181758727908594
   PubMed Web of Science ®Google Scholar
• ColemanRLOzaAMLorussoDRucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialLancet2017390101061949196128916367
   PubMed Web of Science ®Google Scholar
• FarmerHMccabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• BryantHESchultzNThomasHDErratum: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature20074477142346918
   Web of Science ®Google Scholar
• CantorDThe frustrations of families: Henry Lynch, heredity, and cancer controlMed Hist200650327930216902702
   PubMed Web of Science ®Google Scholar
• KingMCMarksJHMandellJBNew York Breast Cancer Study GroupBreast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2Science2003302564564364614576434
   PubMed Web of Science ®Google Scholar
• HallJMLeeMKNewmanBLinkage of early-onset familial breast cancer to chromosome 17q21Science19902504988168416892270482
   PubMed Web of Science ®Google Scholar
• WoosterRBignellGLancasterJIdentification of the breast cancer susceptibility gene BRCA2Nature199537865597897928524414
   PubMed Web of Science ®Google Scholar
• LuKKauffNPowellBACOG practice bulletin 103: Hereditary breast and ovarian cancer syndromeObstet Gynecol200911410619220219546798
   PubMed Web of Science ®Google Scholar
• JavleMCurtinNJThe role of PARP in DNA repair and its therapeutic exploitationBr J Cancer201110581114112221989215
   PubMed Web of Science ®Google Scholar
• HelledayTThe underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandingsMol Oncol20115438739321821475
   PubMed Web of Science ®Google Scholar
• HollidayRA mechanism for gene conversion in fungiGenet Res196452282304
   Web of Science ®Google Scholar
• MirzaMRMonkBJHerrstedtJNiraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancerN Engl J Med2016375222154216427717299
   PubMed Web of Science ®Google Scholar
• MeiLChenHWeiDMMaintenance chemotherapy for ovarian cancerCochrane Database Syst Rev20132728CD007414
   Google Scholar
• PecorelliSFavalliGGadducciAPhase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the after-6 protocol 1J Clin Oncol200927284642464819704064
   PubMed Web of Science ®Google Scholar
• BurgerRABradyMFBookmanMAIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
   PubMed Web of Science ®Google Scholar
• GourleyCFriedlanderMMatulonisUAClinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)J Clin Oncol20173515 Suppl5533
   Web of Science ®Google Scholar
• Pujade-LauraineELedermannJASelleFOlaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Oncol20171891274128428754483
   PubMed Web of Science ®Google Scholar
• PlummerRMiddletonMWilsonRFirst in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumorsJ Clin Oncol20052316 Suppl3065
   Google Scholar
• DrewYMulliganEAVongWTTherapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2J Natl Cancer Inst2011103433434621183737
   PubMedGoogle Scholar
• IhnenMZu EulenburgCKolarovaTTherapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancerMol Cancer Ther20131261002101523729402
   PubMed Web of Science ®Google Scholar
• ZanjirbandMCurtinNEdmondsonRJLunecJCombination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancerOncotarget2017841697796979629050241
   PubMedGoogle Scholar
• KossatzSCarneyBFarleyCWeberWADrainCMReinerTDirect imaging of drug distribution and target engagement of the PARP inhibitor rucaparibJ Nucl Med20185981316132029572258
   PubMed Web of Science ®Google Scholar
• AlmeidaGSBawnCMGallerMPARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRSNMR Biomed2017309e3736e3738
   Web of Science ®Google Scholar
• MccruddenCMO’RourkeMGCherryKEVasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfPLoS One2015102e011818725689628
   PubMed Web of Science ®Google Scholar
• AliMTelferBAMccruddenCVasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?Clin Cancer Res200915196106611219789326
   PubMed Web of Science ®Google Scholar
• KristeleitRShapiroGIBurrisHAA phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumorsClin Cancer Res201723154095410628264872
   PubMed Web of Science ®Google Scholar
• WilsonRHEvansTJMiddletonMRA phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursBr J Cancer2017116788489228222073
   PubMed Web of Science ®Google Scholar
• KondrashovaONguyenMShield-ArtinKSecondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinomaCancer Discov20177998499828588062
   PubMed Web of Science ®Google Scholar
• MccormickADonoghuePDixonMOvarian cancers harbor defects in nonhomologous end joining resulting in resistance to rucaparibClin Cancer Res20172382050206027702817
   PubMed Web of Science ®Google Scholar
• OzaAMTinkerAVOakninAAntitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Gynecol Oncol2017147226727528882436
   PubMed Web of Science ®Google Scholar
• LiuAYCohenJGWalshCSHolschneiderCHSinnoAKA cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancerGynecol Oncol20171471196
   Web of Science ®Google Scholar
• MooreKColomboNScambiaGMaintenance olaparib in patients with newly diagnosed advanced ovarian cancerN Engl J Med Epub20181021
   Web of Science ®Google Scholar